These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 8053886)

  • 1. EMACO in high risk gestational trophoblast disease--the Australian experience. Gestational Trophoblast Subcommittee, Clinical Oncological Society of Australia.
    Quinn M; Murray J; Friedlander M; Steigrad S; Khoo S; Marsden D; Hammond I; Jobling T
    Aust N Z J Obstet Gynaecol; 1994 Feb; 34(1):90-2. PubMed ID: 8053886
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Methotrexate monotherapy for high-risk gestational trophoblastic neoplasia after therapy with etoposide, methotrexate, and dactinomycin: a case report.
    Taran A; Ignatov A; Smith B; Bischoff J; Costa SD
    Am J Obstet Gynecol; 2008 Nov; 199(5):e6-8. PubMed ID: 18984073
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Alternating weekly chemotherapy with etoposide-methotrexate-dactinomycin/cyclophosphamide-vincristine for high-risk gestational trophoblastic disease.
    Soper JT; Evans AC; Clarke-Pearson DL; Berchuck A; Rodriguez G; Hammond CB
    Obstet Gynecol; 1994 Jan; 83(1):113-7. PubMed ID: 8272290
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Etoposide, methotrexate, actinomycin D, cyclophosphamide, and vincristine for the treatment of metastatic, high-risk gestational trophoblastic disease.
    Schink JC; Singh DK; Rademaker AW; Miller DS; Lurain JR
    Obstet Gynecol; 1992 Nov; 80(5):817-20. PubMed ID: 1328977
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High-risk metastatic gestational trophoblastic disease. A new dose-intensive, multiagent chemotherapeutic regimen.
    Surwit EA; Childers JM
    J Reprod Med; 1991 Jan; 36(1):45-8. PubMed ID: 1848900
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Low-risk persistent gestational trophoblastic disease: outcome after initial treatment with low-dose methotrexate and folinic acid from 1992 to 2000.
    McNeish IA; Strickland S; Holden L; Rustin GJ; Foskett M; Seckl MJ; Newlands ES
    J Clin Oncol; 2002 Apr; 20(7):1838-44. PubMed ID: 11919242
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Etoposide and cisplatin/etoposide, methotrexate, and actinomycin D (EMA) chemotherapy for patients with high-risk gestational trophoblastic tumors refractory to EMA/cyclophosphamide and vincristine chemotherapy and patients presenting with metastatic placental site trophoblastic tumors.
    Newlands ES; Mulholland PJ; Holden L; Seckl MJ; Rustin GJ
    J Clin Oncol; 2000 Feb; 18(4):854-9. PubMed ID: 10673528
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Plasma methotrexate levels in patients receiving etoposide, methotrexate, actinomycin, cyclophosphamide, and vincristine (EMA-CO) chemotherapy for trophoblastic neoplasia.
    Kohorn EI
    Gynecol Oncol; 1993 Sep; 50(3):300-4. PubMed ID: 8406191
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Developments in chemotherapy for medium- and high-risk patients with gestational trophoblastic tumours (1979-1984).
    Newlands ES; Bagshawe KD; Begent RH; Rustin GJ; Holden L; Dent J
    Br J Obstet Gynaecol; 1986 Jan; 93(1):63-9. PubMed ID: 3002420
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Gestational trophoblastic disease.
    Hammond CB; Olt GJ
    Curr Ther Endocrinol Metab; 1994; 5():567-70. PubMed ID: 7704794
    [No Abstract]   [Full Text] [Related]  

  • 11. [Treatment of patients with trophoblastic tumors in the Academic Medical Center: 31 patients in 10 years, 1983-1992].
    Laan R; Bakker P; Lammes FB
    Ned Tijdschr Geneeskd; 1995 Sep; 139(36):1829-34. PubMed ID: 7477506
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combination chemotherapy with methotrexate, etoposide, and actinomycin D for high-risk gestational trophoblastic tumors.
    Matsui H; Suzuka K; Iitsuka Y; Seki K; Sekiya S
    Gynecol Oncol; 2000 Jul; 78(1):28-31. PubMed ID: 10873405
    [TBL] [Abstract][Full Text] [Related]  

  • 13. EMA/CO for high-risk gestational trophoblastic tumors: results from a cohort of 272 patients.
    Bower M; Newlands ES; Holden L; Short D; Brock C; Rustin GJ; Begent RH; Bagshawe KD
    J Clin Oncol; 1997 Jul; 15(7):2636-43. PubMed ID: 9215835
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of multiagent chemotherapy and independent risk factors in the treatment of high-risk GTT--25 years experiences of KRI-TRD.
    Kim SJ; Bae SN; Kim JH; Kim CT; Han KT; Lee JM; Jung JK
    Int J Gynaecol Obstet; 1998 Apr; 60 Suppl 1():S85-96. PubMed ID: 9833620
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A novel strategy using G-CSF to support EMA/CO for high-risk gestational trophoblastic disease.
    Hartenbach EM; Saltzman AK; Carter JR; Twiggs LB
    Gynecol Oncol; 1995 Jan; 56(1):105-8. PubMed ID: 7529741
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Management of high-risk gestational trophoblastic neoplasia with etoposide, methotrexate, actinomycin D, cyclophosphamide, vincristine chemotherapy.
    Cyriac S; Rajendranath R; Sridevi V; Sagar TG
    J Reprod Med; 2011; 56(5-6):219-23. PubMed ID: 21682117
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Feasibility of central co-ordinated EMA/CO for gestational trophoblastic disease in the Netherlands.
    van der Houwen C; Rietbroek RC; Lok CA; Ten Kate-Booij MJ; Lammes FB; Ansink AC
    BJOG; 2004 Feb; 111(2):143-7. PubMed ID: 14723751
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Etoposide (VP-16) in gynecologic malignancy].
    Kanazawa K; Moromizato H
    Gan To Kagaku Ryoho; 1996 Dec; 23(14):1925-8. PubMed ID: 8978799
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment of gestational trophoblastic tumors.
    Lurain JR
    Curr Treat Options Oncol; 2002 Apr; 3(2):113-24. PubMed ID: 12057074
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pulmonary hypertension--a rare presentation of choriocarcinoma.
    Gangadharan VP; Chitrathara K; Sivaramakrishnan R; Satishkumar K; Nair MK
    Acta Oncol; 1993; 32(4):461-2. PubMed ID: 8396399
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.